Background Glutathione S-transferase M3 (GSTM3) is an important member of the GSTs that plays a critical role in the development of head and neck cancer (HNC). Several studies have investigated between the GSTM3 A/B polymorphism and risk of HNC, however, the results remain controversial. The aim of this meta-analysis is to evaluate the association between the GSTM3 A/B polymorphism and the risk of HNC. Methods All eligible case-control studies published up to July 2013 were identified by searching PubMed and Web of Science. The HNC risk associated with the GSTM3 A/B polymorphism was estimated for each study by odds ratios (OR) together with its 95% confidence interval (CI), respectively. Results Fourteen studies from ten publications with 2110 patients and 2259 controls were included. Overall, the GSTM3 A/B polymorphism was associated with a decreased risk of HNC using the dominant model, homozygote comparison model and heterozygote comparison model (OR = 0.82, 95%CI: 0.71–0.94; OR = 0.67, 95%CI: 0.49–0.94; and OR = 0.84, 95%CI: 0.73–0.97, respectively); besides, in stratification analyses by ethnicity, similar results were observed in Caucasian populations. Stratification by tumor site indicated that the GSTM3 polymorphism was associated with a decreased risk of laryngeal cancer under recessive model and homozygote comparison (OR = 0.52, 95%CI: 0.30–0.89; and OR = 0.50, 95%CI: 0.29–0.87, respectively); By stratifying source of control, decreased cancer risk was observed in hospital-based population under all genetic models (OR = 0.67, 95%CI: 0.56–0.81 for the dominant model; OR = 0.66, 95%CI: 0.46–0.95 for the recessive model; OR = 0.55, 95%CI: 0.37–0.83 for the homozygote comparison model, and OR = 0.70, 95%CI: 0.58–0.84 for the heterozygote comparison model). Conclusions This meta-analysis suggests that the GSTM3 A/B polymorphism may be an important protective factor for HNC, especially of laryngeal cancer and Caucasian populations.
References
[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
[2]
Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S (1998) Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 18: 4779–4786.
[3]
Kim L, King T, Agulnik M (2010) Head and neck cancer: changing epidemiology and public health implications. Oncology (Williston Park) 24: 915–919,924.
[4]
Ketterer B (1988) Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res 202: 343–361.
[5]
Shi Y, Lee JS, Galvin KM (1997) Everything you have ever wanted to know about Yin Yang 1……. Biochim Biophys Acta 1332: F49–F66.
[6]
Yengi L, Inskip A, Gilford J, Alldersea J, Bailey L, et al. (1996) Polymorphism at the glutathione S-transferase locus GSTM3: interactions with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res 56: 1974–1977.
[7]
Inskip A, Elexperu-Camiruaga J, Buxton N, Dias PS, MacIntosh J, et al. (1995) Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Biochem J 312: 713–716.
[8]
Jahnke V, Strange R, Matthias C, Fryer A (1997) Glutathione S-transferase and cytochrome P450 genotypes as a risk factors for laryngeal carcinoma. Eur Arch Otorhinolaryngol 254: 147–149.
[9]
Chatzimichalis M, Xenellis J, Tzagaroulakis A, Sarof P, Banis K, et al. (2010) GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. J Laryngol Otol 124: 318–323.
[10]
Jahnke V, Matthias C, Fryer A, Strange R (1996) Glutathione S-transferase and cytochrome-P-450 polymorphism as risk factors for squamous cell carcinoma of the larynx. Am J Surg 172: 671–673.
[11]
Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, Dayer P, et al. (1999a) Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer 81: 44–48.
[12]
Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, Dayer P, et al. (1999b) Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. Cancer Epidemiol Biomarkers Prev 8: 185–188.
[13]
Matthias C, Bockmühl U, Jahnke V, Petersen I, Dietel M, et al. (1998a) [Effect of gene polymorphism on detoxifying glutathione-S-transferase enzymes on chromosomal stability of squamous epithelial carcinomas in the area of the head-neck]. Laryngorhinootologie 77: 201–206 (Article in German).
[14]
Matthias C, Bockmühl U, Jahnke V, Jones PW, Hayes JD, et al. (1998b) Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 8: 91–100.
[15]
Matthias C, Jahnke V, Fryer AA, Strange RC (2003) [First results on the influence of polymorphisms at glutathione S-transferase, cytochrome P450, and tumor necrosis factor gene loci on the development of multiple head and neck cancer]. Laryngorhinootologie 82: 25–30 (Article in German).
[16]
Park LY, Muscat JE, Kaur T, Schantz SP, Stern JC, et al. (2000) Comparison of GSTM polymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics 10: 123–131.
[17]
Rydzanicz M, Wierzbicka M, Gajecka M, Szyfter W, Szyfter K (2005) The impact of genetic factors on the incidence of multiple primary tumors (MPT) of the head and neck. Cancer Lett 224: 263–278.
[18]
To-Figueras J, Gené M, Gómez-Catalán J, Piqué E, Borrego N, et al. (2002) Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk. Cancer Lett 187: 95–101.
[19]
Buch SC, Notani PN, Bhisey RA (2002) Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 23: 803–807.
[20]
Majumder M, Sikdar N, Paul RR, Roy B (2005) Increased risk of oral leukoplakia and cancer among mixed tobacco users carrying XRCC1 variant haplotypes and cancer among smokers carrying two risk genotypes: one on each of two loci, GSTM3 and XRCC1 (Codon 280). Cancer Epidemiol Biomarkers Prev 14: 2106–2112.
[21]
Marques CF, Koifman S, Koifman RJ, Boffetta P, Brennan P, et al. (2006) Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case-control study in Rio de Janeiro. Oral Oncol 42: 632–637.
[22]
Sikdar N, Paul RR, Roy B (2004) Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int J Cancer 109: 95–101.
[23]
Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820–826.
[24]
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
[25]
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
[26]
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101.
[27]
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
[28]
Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, et al. (2007) Role of GSTM3 polymorphism in the risk of developing esophageal cancer. Cancer Epidemiol Biomarkers Prev 16: 178–181.
[29]
Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT, et al. (2001) Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis 22: 1053–1060.
[30]
Holley SL, Rajagopal R, Hoban PR, Deakin M, Fawole AS, et al. (2006) Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int J Oncol 28: 231–236.
[31]
Saarikoski ST, Voho A, Reinikainen M, Anttila S, Karjalainen A, et al. (1998) Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 77: 516–521.
[32]
Pandey SN, Jain M, Nigam P, Choudhuri G, Mittal B (2006) Genetic polymorphisms in GSTM1, GSTT1, GSTP1, GSTM3 and the susceptibility to gallbladder cancer in North India. Biomarkers 11: 250–261.
[33]
Schwartzbaum JA, Ahlbom A, L？nn S, Warholm M, Rannug A, et al. (2007) An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol Biomarkers Prev 16: 559–565.
[34]
Hirvonen A (1999) Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer. Environ Health Perspect 107: 37–47.
[35]
Wu X, Zhao H, Suk R, Christiani DC (2004) Genetic susceptibility to tobacco-related cancer. Oncogene 23: 6500–6523.
[36]
Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and contribution of isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445–600.
[37]
Butkiewicz D, Grzybowska E, Phillips DH, Hemminki K, Chorazy M (2000) Polymorphisms of the GSTP1 and GSTM1genes and PAH-DNA adducts in human mononuclear white blood cells. Environ Mol Mutagen 35: 99–105.
